These two genera appear together on nearly every probiotic label, usually presented as a matched pair.
They aren’t. They live in different parts of the gut, tolerate oxygen differently, metabolise sugars by different pathways — and one of them isn’t really a resident at all.
Different addresses
The gut is not one environment. Oxygen levels, pH, transit speed and available nutrients all change from the small intestine to the colon, and bacterial abundance rises sharply along that route[5].
Lactobacillus occupies the upper gut and beyond. It’s found across the oral cavity, stomach, small intestine and vaginal tract[1]. Within the gut, populations are generally more numerous in the small intestine[1].
Bifidobacterium is different. It is overwhelmingly concentrated in the large intestine, which is its natural and primary ecological niche[1].
The reason is oxygen tolerance.
Bifidobacterium is an obligate anaerobe — it cannot survive where oxygen is present[2][3]. The colon, furthest from the oxygen-rich upper tract, suits it.
Lactobacillus is aerotolerant[4]. It tolerates oxygen while still metabolising fermentatively, which lets it occupy the upper gut, the mouth, and the vagina — places Bifidobacterium cannot.
One genus is limited by oxygen; the other isn’t. That single difference explains most of the distribution.
One of them is mostly a visitor
Here’s the finding that changed how I read these labels.
Lactobacilli are not particularly dominant in any part of the healthy adult gut except in transient peaks after fermented food intake[4].
And many gut strains are considered transient — primarily derived from ingested fermented foods or the oral cavity[1].
So a large share of the *Lactobacillus* in an adult gut is passing through rather than living there.
Its biggest human niche is actually the vagina[4], where its acid tolerance lets it dominate by producing lactic acid and maintaining a protective low pH[1].
*Bifidobacterium*, by contrast, genuinely colonises. It plays a key role in remodeling the gut microbiota after colonization[3], and one species alone — *B. longum* — accounts for a mean 45.22% of the genus in the human gut[2].
This reframes what a probiotic is doing. For *Bifidobacterium*, the goal may be establishing residence. For *Lactobacillus*, transient passage through the small intestine may be closer to how it works natively.
Different metabolism
The two genera also break down sugars by different routes.
Bifidobacterium uses the “bifid shunt”, characterised by the enzyme fructose-6-phosphate phosphoketolase[3]. This pathway is unique enough to the genus that it’s used as an identifying marker.
It lets *Bifidobacterium* metabolise dietary carbohydrates that resist degradation in the stomach and small intestine[2] — fibres that arrive at the colon intact, which is precisely what’s available there.
Lactobacillus can use less oxygen to produce more lactic acid[3].
Each metabolism suits its address. Bifidobacteria specialise in the leftovers that reach the colon; lactobacilli work on sugars available higher up.
| Lactobacillus | Bifidobacterium | |
| Primary gut location | Small intestine | Large intestine (colon) |
| Oxygen | Aerotolerant | Obligate anaerobe |
| Other niches | Mouth, vagina, stomach | Gut primarily |
| Residence | Often transient | Colonises |
| Metabolism | Lactic acid fermentation | Bifid shunt (F6PPK) |
| Dominant species | Varies | *B. longum* (45.22%) |
[Table 1] The two genera compared · Source: Compilation of relevant literature[1][3][4][5]
The name problem
One practical complication, following from the strain naming post.
**In April 2020, the single genus *Lactobacillus* was split into 25 new genera** within the family Lactobacillaceae[4].
Many familiar species were renamed. What was *Lactobacillus rhamnosus* became *Lacticaseibacillus rhamnosus*; *Lactobacillus plantarum* became *Lactiplantibacillus plantarum*.
This is why Korean regulators updated ingredient naming, as covered in the CFU labelling post — the scientific names on labels had to change because the taxonomy underneath them did.
Practically: a product listing “Lactobacillus rhamnosus” and one listing “Lacticaseibacillus rhamnosus” may be naming the same organism. Older and newer labels use different conventions.
A bit more detail — on why the split happened. The original genus had become extraordinarily diverse, containing organisms less related to each other than members of separate genera in other bacterial families. The 2020 reclassification grouped them by actual genetic relatedness. *Bifidobacterium* was unaffected — it was never in *Lactobacillus* and sits in a different phylum entirely, Actinobacteria rather than Firmicutes.
What this means for reading a label
Four things follow.
Genus tells you roughly where a strain works. Bifidobacterium acts mainly in the colon; Lactobacillus mainly higher up and, for vaginal strains, elsewhere entirely.
Oxygen sensitivity affects handling. Bifidobacterium is an obligate anaerobe and more sensitive to oxygen[3] — relevant to the storage and viability issues covered in the CFU post.
“Contains both” isn’t automatically better. They occupy different niches, so a product containing both is covering two locations rather than doubling coverage of one.
The strain designation still matters most. As covered in the strain naming post, genus and species don’t determine function — the last part of the name does. Two *Lactobacillus rhamnosus* strains can behave differently.
If you’re in Korea
Two notes.
The 19 notified probiotic species in Korea’s Health Functional Food Code include both genera — as covered earlier, eleven Lactobacillus and four Bifidobacterium species, plus Enterococcus, Lactococcus and Streptococcus.
Ingredient names on Korean labels were updated to reflect the 2020 reclassification. A product manufactured before and after that change may show different scientific names for the same organism.
And the approved wording covers proliferation of beneficial bacteria, suppression of harmful bacteria, and bowel regularity — nothing in it distinguishes between the two genera. The regulatory claim is the same regardless of which you’re taking.
Closing
The most useful correction here was about residence.
I’d assumed both genera were gut residents that probiotics topped up. But lactobacilli aren’t particularly dominant anywhere in the healthy adult gut except in transient peaks after fermented food — and their largest human niche is the vagina, not the intestine.
Bifidobacteria genuinely live in the colon, in numbers, with a metabolic pathway suited to what arrives there.
So the two aren’t a matched pair filling the same role at different addresses. One is a resident specialist and the other is largely a well-tolerated visitor.
None of which tells you whether either helps with anything specific — that remains a strain-level question, as this series keeps finding. But it does explain why the label lists two names, and what each is doing there.
Key Terms
- Genus — the broader classification level; the first word in a scientific name.
- Obligate anaerobe — an organism that cannot survive in the presence of oxygen.
- Aerotolerant — able to survive oxygen exposure while still metabolising without it.
- Transient — passing through rather than establishing residence.
- Colonise — to establish a stable resident population.
- Bifid shunt — the distinctive sugar-metabolising pathway used by Bifidobacterium.
At a Glance
- Lactobacillus is more numerous in the small intestine, and also occupies mouth, stomach and vagina
- Bifidobacterium is overwhelmingly concentrated in the colon
- The difference is oxygen: Bifidobacterium is an obligate anaerobe, Lactobacillus is aerotolerant
- Lactobacilli are not particularly dominant anywhere in the healthy adult gut except transient peaks after fermented food
- Many gut lactobacilli are transient, from food or the oral cavity; the vagina is their largest human niche
- Bifidobacterium genuinely colonises — ***B. longum* averages 45.22%** of the genus in the human gut
- Bifidobacterium uses the bifid shunt to metabolise carbohydrates that resist digestion higher up
- In 2020 the genus *Lactobacillus* was split into 25 genera** — older and newer labels may name the same organism different
※ This article describes microbial biology and is for general information only. It does not replace medical advice, and does not evaluate any specific product. If you take immunosuppressive medication or have a serious illness, consult a clinician before taking probiotics, and stop and seek advice if adverse symptoms occur. Recognised ingredient lists and naming conventions are revised periodically — confirm current details on official sources.
References
- “Lactobacillus and Bifidobacterium: What’s the Difference?”, ScienceInsights (habitat distribution, oxygen tolerance, transient strains, vaginal niche), https://scienceinsights.org/lactobacillus-and-bifidobacterium-whats-the-difference/
- “Factors involved in the abundant dominance of Bifidobacterium longum within the genus in the human gut”, ScienceDirect (obligate anaerobe characterisation; species abundance data), https://www.sciencedirect.com/science/article/abs/pii/S221242922401068X
- “Bifidobacterium — an overview”, ScienceDirect Topics (bifid shunt and F6PPK; oxygen sensitivity comparison), https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/bifidobacterium
- “All The Different Strains Of Lactobacillus: A Complete Guide”, MyBioHack (2020 reclassification into 25 genera; aerotolerance; transient dominance), https://www.mybiohack.com/blog/lactobacillus-strains-guide
- “Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective”, PMC (relative abundance across gastrointestinal compartments), https://pmc.ncbi.nlm.nih.gov/articles/PMC11113728/